(Q34208672)

31 July 2017

title

Complex dynamics of hepatitis B virus resistance to adefovir (English)

1 reference

31 July 2017

1 reference

1 reference

5

Christophe Hézode

0 references

Jean-Michel Pawlotsky

6

object named as

Jean-Michel Pawlotsky

0 references

Patrice Nordmann

4

object named as

Patrice Nordmann

1 reference

31 July 2017

Coralie Pallier

1

1 reference

31 July 2017

Christophe Rodriguez

2

1 reference

31 July 2017

Rozenn Brillet

3

1 reference

31 July 2017

Christophe Hézode

5

1 reference

31 July 2017

Jean-Michel Pawlotsky

6

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

31 July 2017

1 reference

31 July 2017

volume

49

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

50-59

1 reference

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

The concept of hepatitis B virus mutant escape

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

Dynamics of hepatitis B virus resistance to lamivudine

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

Management of antiviral resistance in patients with chronic hepatitis B.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

28 July 2018

1 reference

HBV drug resistance: mechanisms, detection and interpretation

21 January 2018

1 reference

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

21 January 2018

1 reference

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

21 January 2018

1 reference

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient

21 January 2018

1 reference

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

21 January 2018

1 reference

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

21 January 2018

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

21 January 2018

1 reference

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

21 January 2018

1 reference

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily

21 January 2018

1 reference

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

21 January 2018

1 reference

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

21 January 2018

1 reference

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

21 January 2018

1 reference

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations

21 January 2018

1 reference

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956748

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19065672

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19065672

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/HEP.22634

1 reference

release_y263mioy4jbynetoardxauvwwi

31 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y263mioy4jbynetoardxauvwwi

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

2956748

1 reference

31 July 2017

1 reference